Pfizer's Phase 3 Study of Elrexfio to Treat Relapsed or Refractory Multiple Myeloma Meets Primary Endpoint

09:12 AM EDT, 10/27/2026 (MT Newswires) -- Pfizer (PFE) said Tuesday that the phase 3 MagnetisMM-32 study of Elrexfio in adults with relapsed or refractory multiple myeloma met its primary endpoint of progression-free survival versus investigator's choice of three standard regimens. The pharmaceutical company said that more than 75% of patients receiving the drug did not experience disease progression or death from any cause at the time of the analysis, with an estimated 68% progression-free survival at 18 months. Data for overall survival, which Pfizer said is a key secondary endpoint of the trial, "remain immature, and follow-up will continue to the next pre-specified OS analysis." Pfizer also said the safety profile of Elrexfio during the study was consistent with its known profile and that no new safety signals were identified.